HUP0203584A2 - Regulation system of expression using nuclear ppar receptors - Google Patents

Regulation system of expression using nuclear ppar receptors

Info

Publication number
HUP0203584A2
HUP0203584A2 HU0203584A HUP0203584A HUP0203584A2 HU P0203584 A2 HUP0203584 A2 HU P0203584A2 HU 0203584 A HU0203584 A HU 0203584A HU P0203584 A HUP0203584 A HU P0203584A HU P0203584 A2 HUP0203584 A2 HU P0203584A2
Authority
HU
Hungary
Prior art keywords
expression
control
regulation system
preparations
ppar receptors
Prior art date
Application number
HU0203584A
Other languages
Hungarian (hu)
Inventor
Joël Crouzet
Raphaël Darteil
Abderrahim Mahfoudi
Bart Staels
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907957A external-priority patent/FR2795425B1/en
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0203584A2 publication Critical patent/HUP0203584A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát transzgének kifejeződésének farmakológiaiszabályozására szolgáló új módszerek és készítmények képezik. Atalálmány tárgyát különösképpen olyan készítmény képezi, amely a) egyszóban forgó nukleinsavat - PPAR válaszelemből és minimálistranszkripciós promóterből álló - indukálható promóter kontrolljaalatt tartalmazó első elemet és b) PPAR-t kódoló nukleinsavattranszkripciós promóter kontrollja alatt tartalmazó második elemettartalmaz, ezek egyidejű, egymástól elválasztott vagy időben eltoltfelhasználásához. A találmány oltalmi körébe tartozik ezenkészítmények és módszerek alkalmazása a kísérleti, klinikai, terápiásvagy diagnosztikai területeken. ÓThe subject of the invention is new methods and preparations for the pharmacological control of the expression of transgenes. The subject of the invention is in particular a preparation which contains a) a first element containing a circulating nucleic acid - consisting of a PPAR response element and a minimal transcriptional promoter - under the control of an inducible promoter and b) a second element containing a nucleic acid encoding PPAR under the control of a transcriptional promoter, for their simultaneous, separated or time-shifted use . The scope of protection of the invention includes the use of these preparations and methods in the experimental, clinical, therapeutic or diagnostic fields. HE

HU0203584A 1999-06-22 2000-06-22 Regulation system of expression using nuclear ppar receptors HUP0203584A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9907957A FR2795425B1 (en) 1999-06-22 1999-06-22 PHARMACOLOGICAL REGULATION OF EXPRESSION SYSTEM USING NUCLEAR RECEPTORS BY AND THEIR LIGANDS
US14972199P 1999-08-20 1999-08-20
PCT/FR2000/001744 WO2000078986A1 (en) 1999-06-22 2000-06-22 Regulation system of expression using nuclear ppar receptors

Publications (1)

Publication Number Publication Date
HUP0203584A2 true HUP0203584A2 (en) 2003-02-28

Family

ID=26234999

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203584A HUP0203584A2 (en) 1999-06-22 2000-06-22 Regulation system of expression using nuclear ppar receptors

Country Status (14)

Country Link
EP (1) EP1190084A1 (en)
JP (1) JP2003503034A (en)
KR (1) KR20020028909A (en)
CN (1) CN1370240A (en)
AU (1) AU6164500A (en)
BR (1) BR0011897A (en)
CA (1) CA2375869A1 (en)
CZ (1) CZ20014609A3 (en)
HU (1) HUP0203584A2 (en)
IL (1) IL147104A0 (en)
MX (1) MXPA01013227A (en)
NO (1) NO20016347L (en)
NZ (1) NZ516678A (en)
WO (1) WO2000078986A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263978B1 (en) * 2000-03-14 2005-12-07 Universite Pierre Et Marie Curie Inflammation-inducible hybrid promoters, vectors containing same and uses thereof
EP1288303A1 (en) * 2001-08-23 2003-03-05 Aventis Pharma S.A. Inducible expression systems employing PPAR transcriptional activators
AU2002333682A1 (en) * 2001-08-02 2003-02-17 Gencell S.A. Inducible expression systems employing ppar transcriptional activators
US10415054B2 (en) * 2013-02-04 2019-09-17 Eth Zurich Designer circuit controlling diet-induced obesity
CN107779454A (en) * 2016-08-31 2018-03-09 上海米络凯生物科技有限公司 The structure of medicaments sifting model based on PPAR γ signal paths and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10502256A (en) * 1994-07-01 1998-03-03 ザ ソールク インスチチュート フォア バイオロジカル スタディズ Mammalian peroxisome proliferator-activated receptor and uses thereof
FR2755699B1 (en) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa NEW CONSTRUCTIONS AND VECTORS FOR TARGETED AND INDUCTIBLE GENE EXPRESSION

Also Published As

Publication number Publication date
NO20016347L (en) 2002-02-19
CZ20014609A3 (en) 2002-05-15
BR0011897A (en) 2002-03-26
NZ516678A (en) 2004-04-30
JP2003503034A (en) 2003-01-28
WO2000078986B1 (en) 2001-04-19
CN1370240A (en) 2002-09-18
WO2000078986A1 (en) 2000-12-28
KR20020028909A (en) 2002-04-17
MXPA01013227A (en) 2002-06-04
IL147104A0 (en) 2002-08-14
AU6164500A (en) 2001-01-09
NO20016347D0 (en) 2001-12-21
EP1190084A1 (en) 2002-03-27
CA2375869A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
DE3867921D1 (en) PRODUCTION OF ALKALI-SOLUBLE AND CARBOXYL GROUP-CONTAINING THICKENERS PRESENT AS AN AQUEOUS EMULSION.
NO874614L (en) PROCEDURE FOR THE MANUFACTURE OF AROMATIC HYDROCARBONS INCLUDING THE USE OF BY-PRODUCTS.
NO990025D0 (en) Hamster EF-1 <alpha> transcriptional regulatory DNA
DE3484217D1 (en) AUTORADIOGRAPHIC EXAMINATION PROCEDURE FOR GENES.
NO891818L (en) T4 RECEPTOR PROTEIN, RELATED DNA SEQUENCES AND PREPARATION thereof.
NO885457D0 (en) PROCEDURE FOR THE PREPARATION OF STABILIZED Zirconia Oxide.
NO880434D0 (en) ANESTHETIC PREPARATIONS AND PROCEDURES FOR USE THEREOF.
HUP0203584A2 (en) Regulation system of expression using nuclear ppar receptors
FR2694296B1 (en) Peptides inhibiting the activity of ras proteins, preparation and use.
DK0655926T3 (en) New probe for tumor diagnosis or tumor therapy
PT599971E (en) PROMOTER OF YEAST AND ITS UTILIZATION
NO985576L (en) Construction and use of genes encoding pathogenic epitopes for the treatment of autoimmune diseases
DK203589A (en) PYRIDYLTHIAZOLIDEIN CARBOXAMIDE DERIVATIVES AND INTERMEDIATES THEREOF, PREPARATIONS CONTAINING THE PRESENT COMPOUNDS AND PROCEDURES FOR THE PREPARATION OF BOTH COMPOUNDS
DK94385D0 (en) PROTEINS, PHARMACEUTICAL PREPARATIONS, GENES, VECTORS, HOST ORGANISMS AND PROCEDURES FOR THEIR PREPARATION
Beighton et al. Hearing impairment and pigmentary disturbance.
FR2694294B1 (en) Yeast promoter and its user.
ATE164396T1 (en) YEAST PROMOTER AND ITS USE
FR2694104B1 (en) Ergonomic communication terminal and its application to an assistance procedure for piloting an aircraft.
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
HUP9800247A2 (en) Promoter for human endoglingene and its use
DE3751114D1 (en) DMD PROBE.
HUP9901346A2 (en) Deltap62, variants thereof, nucleic acid sequences and uses thereof
DE3854273D1 (en) 1,2-di (4-isobutylphenyl) ethane, their preparation and their use as an intermediate.
HUP9902298A2 (en) Derived tyrosine hydroxylase gene expression system
TR25812A (en) DERIVATIVES OF THE NEW AMID, PROCEDURES FOR THIS PREPARATION AND THEIR USE FOR PESTS OF THE PESTS